Radius Health (NASDAQ: RDUS) reported Q1 EPS of ($0.94), $0.02 worse than the analyst estimate of ($0.92). Revenue for the quarter came in at $29.84 million versus the consensus estimate of $35.35 million.

“I am very pleased to see continued strong market share gains by TYMLOS, which we believe is poised to achieve anabolic leadership of new patient starts in the second half of 2019. Our first quarter sales set the stage for continued growth throughout the year as key new account wins come online and temporary Medicare Part D coverage gaps are satisfied,” said Jesper Hoeiland, President and Chief Executive Officer of Radius. “We are confident in our ability to deliver on our full-year financial guidance and attain our goal of leadership in the anabolic market.”

GUIDANCE:

Radius Health sees FY2019 revenue of $160-175 million, versus the consensus of $170.39 million.

For earnings history and earnings-related data on Radius Health (RDUS) click here.